Orenitram vs Uptravi
Side-by-side cost comparison based on Medicare Part D data
Orenitram
Treprostinil (oral)
Manufactured by United Therapeutics
Uptravi
Selexipag
Manufactured by Janssen
Uptravi costs 27% less per claim than Orenitram ($12,882.00 vs $17,719.00). A generic version of Uptravi is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Orenitram | Uptravi |
|---|---|---|
| Avg Cost Per Claim | $17,719.00 | $12,882.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 3,600 | 6,800 |
| Total Claims | 32,000 | 68,000 |
| Annual Cost/Patient | $157,500.00 | $128,824.00 |
| Year-over-Year Change | +12.4% | +12.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | United Therapeutics | Janssen |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Treprostinil (oral) | Selexipag |
Orenitram vs Uptravi: What the Data Shows
Orenitram (Treprostinil (oral)) and Uptravi (Selexipag) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Uptravi costs $12,882.00 per claim, which is 27% less than Orenitram at $17,719.00 per claim.
Medicare spent $567.0M on Orenitram and $876.0M on Uptravi. In terms of patient reach, Uptravi serves more beneficiaries (6,800 vs 3,600).
Year-over-year spending changed +12.4% for Orenitram and +12.6% for Uptravi. Orenitram saw significant spending growth, suggesting increased utilization or price increases. Uptravi saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Uptravi is cheaper at $12,882.00 per claim, compared to $17,719.00 for Orenitram. That makes Uptravi about 27% less expensive per claim based on Medicare Part D data.
Yes, both Orenitram and Uptravi are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Treprostinil (oral) and generic Selexipag can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Orenitram covering 3,600 beneficiaries, and $876.0M on Uptravi covering 6,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.